Pathology & Oncology Research

, Volume 21, Issue 4, pp 1273–1275 | Cite as

Elevated Expression of CD109 in Esophageal Squamous Cell Carcinoma

  • Fengyun Dong
  • Fuhong Liu
  • Suhua Yan
  • Xiaochun Liu
  • Zhongmin JiangEmail author
  • Ju LiuEmail author
Letter to Editor

To the Editor,

Esophageal squamous cell carcinoma (ESCC) accounts for approximately one-sixth of all cancer-related mortality, occurring at a higher incidence in Asian countries [1]. Though the effectiveness of surgical treatments has significantly improved, the prognosis of ESCC remains poor, with a 5-year survival rate of less than 10 % [1]. Recent studies suggest that the transforming growth factor-β (TGF-β) signaling may involve in malignancy development of ESCC [2, 3]. Altered expression of TGF-β receptors contributes to ESCC progression, and elevated expression of inhibitory proteins of TGF-β signaling correlates with poor prognosis of ESCC [2]. CD109, a member of the α2-macroglobulin/complement family, is a co-receptor of TGF-β1 [4]. CD109 suppresses TGF-β signaling by promoting internalization of TGF-β receptors [4]. The transcription of CD109 is up-regulated in some ESCC samples [5]. However, the protein level of CD109 in ESCCs has not yet been examined. In this limited...


Esophageal Squamous Cell Carcinoma CD109 Expression CD109 Esophageal Squamous Cell Carcinoma Patient Squamous Epithelial Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was supported by Shandong Taishan Scholarship (Ju Liu) from Shandong Provincial Government. Ju Liu confirms that the work was performed independence from the sponsors and the content of the article has not been influenced by the sponsors.

Author Contribution

Guarantor of the article: Ju Liu, Zhongmin Jiang

Specific author contributions:

FD, FL, YS, XL: Data collection, analysis and interpretation; drafting the manuscript; final approval of the version to be published.

ZJ, JL: project conception/initiation; experimental design; drafting of the manuscript; critical revision; final approval of the version to be published.

Conflict of interest



  1. 1.
    Stoner GD, Wang LS, Chen T (2007) Chemoprevention of esophageal squamous cell carcinoma. Toxicol Appl Pharmacol 224(3):337–349. doi: 10.1016/j.taap.2007.01.030 PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Osawa H, Nakajima M, Kato H, Fukuchi M, Kuwano H (2004) Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGF-beta superfamily, in esophageal squamous cell carcinoma. Anticancer Res 24(6):3703–3709PubMedGoogle Scholar
  3. 3.
    Megumi K, Ishigami S, Uchikado Y, Kita Y, Okumura H, Matsumoto M, Uenosono Y, Arigami T, Kijima Y, Kitazono M, Shinchi H, Ueno S, Natsugoe S (2012) Clinicopathological significance of BMP7 expression in esophageal squamous cell carcinoma. Ann Surg Oncol 19(6):2066–2071. doi: 10.1245/s10434-011-2024-5 PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S, Bizet AA, Philip A (2006) Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. FASEB J Off Publ Fed Am Soc Exp Biol 20(9):1525–1527. doi: 10.1096/fj.05-5229fje Google Scholar
  5. 5.
    Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, Yuasa N, Takahashi T, Yatabe Y, Murakumo Y, Zhang JM, Nimura Y, Takahashi M (2004) Expression of CD109 in human cancer. Oncogene 23(20):3716–3720. doi: 10.1038/sj.onc.1207418 CrossRefPubMedGoogle Scholar
  6. 6.
    Ozbay PO, Ekinci T, Yigit S, Yavuzcan A, Uysal S, Soylu F, Cakalagaoglu F (2013) Investigation of prognostic significance of CD109 expression in women with vulvar squamous cell carcinoma. Onco Targets Ther 6:621–627. doi: 10.2147/OTT.S41069 PubMedCentralPubMedGoogle Scholar
  7. 7.
    Zhang JM, Hashimoto M, Kawai K, Murakumo Y, Sato T, Ichihara M, Nakamura S, Takahashi M (2005) CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int 55(4):165–169. doi: 10.1111/j.1440-1827.2005.01807.x CrossRefPubMedGoogle Scholar
  8. 8.
    Duff B, Weigel JA, Bourne P, Weigel PH, McGary CT (2002) Endothelium in hepatic cavernous hemangiomas does not express the hyaluronan receptor for endocytosis. Hum Pathol 33(3):265–269CrossRefPubMedGoogle Scholar
  9. 9.
    Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, Pellegatta S, Mancuso P, Porrati P, Di Stefano AL, Ceroni M, Bertolini F, Finocchiaro G, Eoli M (2013) Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One 8(9):e74345. doi: 10.1371/journal.pone.0074345 PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, Tohnai I, Ueda M, Takahashi M (2008) Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci 99(10):1916–1923. doi: 10.1111/j.1349-7006.2008.00949.x PubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2015

Authors and Affiliations

  1. 1.Shandong Provincial Qianfoshan HospitalShandong UniversityJinanChina
  2. 2.Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations